-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 27, CDE's official website showed that LY05008 of Luye Pharmaceutical's subsidiary Boan Biotechnology was approved for clinical use
From: CDE official website
GLP-1 receptor agonists are a new driving force for the rapid growth of the diabetes field in recent years, and the market size has been close to half of insulin products
Trulicity (Trulicity) is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly and injected once a week.
In addition to being approved for the treatment of type 2 diabetes, Trulicity was approved by the FDA in 2020 to reduce the risk of major adverse vascular events (MACE) in adult patients with type 2 diabetes who have cardiovascular (CV) diseases or have multiple Cardiovascular risk factors
In China, Eli Lilly's Duyida was approved for listing in February 2019.
Competition details of dulaglutide and similar drugs (Insight)
From: Insight database (http://db.